Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Beyond TED | Explore Viridian's expansion into FcRn-mediated diseases with VRDN-008, potentially opening new market opportunities beyond thyroid eye disease treatment |
Analyst Optimism | Consensus "Strong Buy" recommendation with price targets ranging from $19 to $61, averaging around $38, reflecting market confidence in VRDN's potential |
Financial Strength | With over $630 million in cash, Viridian is well-positioned to fund operations into 2027, supporting ongoing clinical programs and potential launch |
Promising TED Treatment | Viridian's veligrotug shows compelling long-term efficacy for thyroid eye disease, with 70% of responders maintaining results at week 52 |
Metrics to compare | VRDN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVRDNPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.3x | −4.6x | −0.5x | |
PEG Ratio | 0.35 | −0.02 | 0.00 | |
Price / Book | 3.1x | 2.4x | 2.6x | |
Price / LTM Sales | 4,290.3x | 10.8x | 3.1x | |
Upside (Analyst Target) | 142.5% | 182.7% | 50.4% | |
Fair Value Upside | Unlock | 1.2% | 8.7% | Unlock |